Preface

Epidemiologic data published in 2023 suggest that nonalcoholic fatty liver (NAFLD) and nonalcoholic steatohepatitis (NASH) affect around 30% and 5% of the world population and is on track to become the most common cause of cirrhosis and hepatocellular carcinoma (HCC), the most common cause for liver death, and the most common indication for liver transplantation. Driven by the global pandemic of obesity and type 2 diabetes, the global burden of NAFLD can be measured not only in clinical terms (liver mortality, cirrhosis, HCC) but also by its negative impact on patient-reported outcomes and the economic burden of the disease.

Source: Clinics in Liver Disease - March 9, 2023 Category: Gastroenterology Authors: Zobair M. Younossi Source Type: research